NCT00144963 - Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

Vincristine Sulfate Liposomes Injection

Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).

DRUG

Dexamethasone

Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).

Trial Locations (3)

Emory University, Atlanta

University of Chicago Medical Center, Chicago

University of Texas M.D. Anderson Cancer Center, Houston